問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

魏秀娟
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

魏秀娟

Chung Shan Medical University Hospital

Division of Dermatology

List

8Cases

2022-11-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-04-01 - 2028-12-31

Phase II

Active
An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis

  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2018-08-31 - 2025-11-11

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-09-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-07-31 - 2026-05-27

Phase II

Completed
Master Protocol Title: A Master Protocol for Randomized, Controlled, Phase 2 Clinical Trials of Multiple Interventions for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis ISA Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    f Adults with Moderate-to-Severe Atopic Dermatitis

  • Test Drug

    N/A

Participate Sites
8Sites

Recruiting8Sites

2023-05-15 - 2030-04-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-08-31 - 2025-06-30

Phase III

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Upadacitinib

Participate Sites
4Sites

Terminated4Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2023-07-31 - 2026-05-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB